ACC GUIDELINES Bundle (free trial)

UA/NSTEMI (ACC)

ACC GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/244063

Contents of this Issue

Navigation

Page 39 of 49

Treatment Blood Pressure Control ÎÎBlood pressure control according to JNC 7 guidelines is recommended (ie, blood pressure <140/90 mm Hg or <130/80 mm Hg if the patient has diabetes mellitus or CKD). (I-A) ÎÎAdditional measures recommended to treat and control blood pressure include the following: •  Patients should initiate and/or maintain lifestyle modifications, including weight control, increased physical activity, alcohol moderation, sodium reduction, and emphasis on increased consumption of fresh fruits, vegetables, and low-fat dairy products. (I-B) •  For patients with blood pressure greater than or equal to 140/90 mm Hg (or ≥130/80 mm Hg for individuals with CKD or diabetes mellitus), it is useful to add blood pressure medication as tolerated, treating initially with beta blockers and/or ACE inhibitors, with addition of other drugs such as thiazides as needed to achieve target blood pressure. (I-A) Diabetes Mellitus ÎÎDiabetes management should include lifestyle and pharmacotherapy measures to achieve a near-normal HbA1c level of less than 7%. (I-B) ÎÎDiabetes management should also include the following: •  Initiate and maintain vigorous modification of other risk factors (eg, physical activity, weight management, blood pressure control, and cholesterol management) as recommended. (I-B) •  It is useful to coordinate the patient's diabetic care with the patient's primary care physician or endocrinologist. (I-C) ÎÎMedical treatment in the acute phase of UA/NSTEMI and decisions on whether to perform stress testing, angiography, and revascularization should be similar in patients with and without diabetes mellitus. (I-A) ÎÎFor patients with UA/NSTEMI and multivessel disease, CABG with use of the internal mammary arteries can be more beneficial than PCI in patients being treated for diabetes mellitus. (IIa-B) ÎÎPCI is reasonable for UA/NSTEMI patients with diabetes mellitus with single-vessel disease and inducible ischemia. (IIa-B) ÎÎIt is reasonable to use an insulin-based regimen to achieve and maintain glucose levels less than 180 mg/dL while avoiding hypoglycemiaa for hospitalized patients with UA/NSTEMI with either a complicated or uncomplicated course. (IIa-B) a 38 There is uncertainty about the ideal target range for glucose necessary to achieve an optimal riskbenefit ratio.

Articles in this issue

Archives of this issue

view archives of ACC GUIDELINES Bundle (free trial) - UA/NSTEMI (ACC)